(0.32%) 5 116.07 points
(0.30%) 38 356 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.36%) $2.03
(0.34%) $2 355.10
(0.50%) $27.67
(4.18%) $960.65
(-0.27%) $0.932
(-0.44%) $10.98
(-0.58%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States...
Stats | |
---|---|
本日の出来高 | 910 216 |
平均出来高 | 262 784 |
時価総額 | 371 901 |
EPS | $0 ( 2024-03-29 ) |
次の収益日 | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.00462 |
ATR14 | $0.0290 (82.98%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-02-14 | Messinger Michael | Buy | 25 000 | Options (Right to Buy) |
2022-05-17 | Barlow Jane F | Buy | 42 000 | Options (Right to Buy) |
2022-05-17 | Sucoff Cary | Buy | 42 000 | Options (Right to Buy) |
2022-05-17 | Otto Michael J. | Buy | 42 000 | Options (Right to Buy) |
2022-05-17 | Low David N. | Buy | 42 000 | Options (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 55 transactions |
Buy: 2 642 000 | Sell: 9 700 000 |
ボリューム 相関
ContraFect Corp 相関
10 最も負の相関 | |
---|---|
TIOAU | -0.973 |
VLAT | -0.97 |
LGVC | -0.97 |
PRLH | -0.967 |
FICV | -0.966 |
TIOA | -0.964 |
SCRM | -0.963 |
IVCP | -0.962 |
INTA | -0.962 |
LDHA | -0.961 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
ContraFect Corp 相関 - 通貨/商品
ContraFect Corp 財務諸表
Annual | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-126.01 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-126.01 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.891 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.240 |
Financial Reports:
No articles found.
ContraFect Corp
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。